Clinical trials: Advanced RCC
Colorectal Cancer (CRC), Endometrial Cancer
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2).
- Conditions
- Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer
- Trial name
- NCT02646748
- Testing
- Pembrolizumab, itacitinib, INCB050465
- Where
- 17 sites in United States
- Volunteers
- 159 people
- Sponsor
- Incyte Corporation
Papillary Renal Cell Carcinoma Type 2
Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
- Trial name
- PAXIPEM (NCT05096390)
- Testing
- Axitinib Oral Tablet [Inlyta], Pembrolizumab Injection [Keytruda]
- Where
- 12 sites in France
- Volunteers
- 72 people
- Sponsor
- Centre Leon Berard
Renal Cell Carcinoma
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
This is a Phase I/II, open-label, multi-center study of axitinib in combination with nivolumab in patients with previously treated and untreated advanced RCC.
- Trial name
- NCT03172754
- Testing
- Nivolumab, Axitinib
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Fox Chase Cancer Center
Renal Cell Carcinoma
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT03592472
- Testing
- Pazopanib, Abexinostat
- Where
- 38 sites in United States, China and 4 more
- Volunteers
- 413 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Advanced Renal Cell Carcinoma
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC.
- Trial name
- TIVO-1 (NCT01030783)
- Testing
- tivozanib (AV-951), Sorafenib
- Where
- 86 sites in United States, Argentina and 14 more
- Volunteers
- 517 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Carcinoma, Renal Cell
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
Purpose of the study: The purpose of this study is to make sorafenib available for patients with advanced Renal Cell Carcinoma, who have failed prior systemic therapy for advanced disease (i.e.
- Trial name
- NCT00492986
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 33 sites in Belgium, Denmark and 9 more
- Volunteers
- 1,150 people
- Sponsor
- Bayer
Metastatic Cancer, Renal Cancer
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
This study will assess the immunomodulatory activity of entinostat in patients with advanced renal cell carcinoma receiving the PD-L1 inhibitor atezolizumab.
- Trial name
- NCT03024437
- Testing
- Atezolizumab, Bevacizumab, Entinostat
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Roberto Pili
Carcinoma, Renal Cell
Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma
In this study, glycosaminoglycan (GAG) profiling in subjects diagnosed with metastatic renal cell carcinoma (mRCC) is hypothesized to be useful in monitoring drug response and predict radiological response.
- Trial name
- NCT02732665
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Jens Nielsen
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
This phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to…
- Conditions
- Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT02761057
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 595 sites in United States, Canada
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, Kidney Cancer
Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma
The purpose of PRORECECA is to test whether adding weekly active patient-reported outcomes to the treatment of patients with metastatic renal cell carcinoma can improve patient-reported physical function.
- Conditions
- Metastatic Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Urologic Cancer
- Trial name
- PRORECECA (NCT05135832)
- Testing
- Electronic patient-reported outcomes regarding symptoms and health-related quality of life
- Where
- Denmark
- Volunteers
- 174 people
- Sponsor
- Herlev and Gentofte Hospital
Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies.
- Conditions
- Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
- Trial name
- NCT07419841
- Testing
- CTX-10726
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Compass Therapeutics
Advanced Non-clear Cell Renal Cell Carcinoma
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
- Trial name
- ASPEN (NCT01108445)
- Testing
- Everolimus, Sunitinib
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 131 people
- Sponsor
- Duke University
Renal Cell Carcinoma
Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.
The purpose of the protocol is to assess the Overall Survival (OS) at 1 year in patients after cabozantinib initiation.
- Trial name
- CAROLINE (NCT04609800)
- Sponsor
- Ipsen
Advanced Cancer, Solid Tumors
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
Primary Objective: -To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of SSG in combination with IFN alpha2b in patients with advanced malignancies.
- Trial name
- NCT00629200
- Testing
- Sodium Stibogluconate, Interferon Alpha-2b
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Anal Cancer, Anxiety Disorder
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
RATIONALE: Gathering information from patients who received treatment for metastatic cancer while participating in a phase II or phase III randomized clinical trial and from patients receiving standard treatment off-trial may…
- Conditions
- Anal Cancer, Anxiety Disorder, Breast Cancer, Depression
- Trial name
- NCT00896467
- Testing
- questionnaire administration, psychosocial assessment and care, quality-of-life assessment
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Oscar Lambret
Kidney Cancer
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
The goal of this clinical research study is to compare pazopanib to temsirolimus in the treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be studied.
- Trial name
- NCT01392183
- Testing
- Pazopanib, Temsirolimus, Quality of Life Assessment
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system.
- Conditions
- Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma, Pancreatic Cancer
- Trial name
- NCT00056537
- Testing
- ABR-217620
- Where
- 3 sites in United States, Norway and 1 more
- Volunteers
- 44 people
- Sponsor
- Active Biotech AB
Clear Cell Renal Cell Carcinoma
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell…
- Trial name
- ENTRATA (NCT03163667)
- Testing
- CB-839, everolimus
- Where
- 38 sites in United States
- Volunteers
- 69 people
- Sponsor
- Calithera Biosciences, Inc
Solid Tumors, Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma
This is a multi-center, open label, non-randomized Phase 1 study, to be conducted in two parts, Part A, and Part B. Part A in solid tumors included the dose escalation phase for evaluating the safety and tolerability profile of…
- Trial name
- NCT02608125
- Testing
- PRN1371
- Where
- 12 sites in United States, Spain
- Volunteers
- 45 people
- Sponsor
- Principia Biopharma, a Sanofi Company